Sutro Biopharma, Inc. (NASDAQ:STRO) traded at $10.9 at last check on Monday, Sep 14, making an upward move of 6.92% on its previous day’s price.
Looking at the stock we see that its previous close was $10.19 and the beta (5Y monthly) reads 0 with the day’s price range being $10.56 – 11.50. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, STRO has a high of $13.91 and a low of $6. The company’s stock has gained about 24.57% over that past 30 days.
Sutro has a market cap of $422.05 Million and is expected to release its quarterly earnings report on August 06, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the STRO stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.55, with the EPS growth for the year raised at -$1.15 for 2020 and -$2.61 for next year. These figures represent -0.53% and at 1.27% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $8.54 Million, with a low of $5Million and a high of $12Million. The median projection represents growth adding up to -30.4% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $31.74 Million, or -25.7% down from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the STRO stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 9 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Sutro Biopharma, Inc. (STRO) stock as a Hold, while 9 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the STRO stock currently stands at 0, and the current price level is 7.01% off its SMA20 and 19.19% from its 50-day simple moving average. The RSI (14) is pointing at 54.17 while the volatility over the past week is 7.37% and drops to 6.91% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 0.9. The average price target for the stock over the next 12 months is $19.38, with the estimates having a low of $16 and a high of $23. These price ends are 46.79% and +111.01% off the current price level respectively, although investors could be excited at the prospect of a +78.9% if the STRO share price touches on the median price of $19.5.
Let’s briefly compare Sutro (STRO) stock to its peers. We find that today’s price change of +6.92% and -0.91% over the past 12 months for STRO competes that of Amgen Inc (AMGN), which has seen its stock price rise 1.46% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.2% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also up 6.92% yet its price remains in the red at -0.91% over the same period. Amgen has a P/E ratio of 20.16 compared to Sutro’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.
Coming back to Sutro Biopharma, Inc. (NASDAQ:STRO), we note that the average 3-month trading volume was 304.78 Million, while that of the preceding 10-day period stands at 738.4 Million. Current shares outstanding are 35.88 Million.
According to data from Thomson Reuters, insiders hold 21.16% of the company’s shares while institutions hold 69.52%. The data shows that short shares as of August 30, 2020, stood at 752.31 Million at a short ratio of 3.61. This represents a 2.1% Short interest in Shares outstanding on August 30, 2020. Shares short dropped in August from the previous month at 767.31 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -0.91% down in year-to-date price movement.